Assessing Exact Sciences (EXAS) Valuation After Recent Share Price Momentum And Tight Fair Value Gap

Exact Sciences stock snapshot

Exact Sciences (EXAS) has drawn investor attention after recent share price moves, with the stock near US$103.94 and return figures over the past year and past 3 years standing out against its 5 year record.

See our latest analysis for Exact Sciences.

The recent move in Exact Sciences' share price to around US$103.94 comes after a strong 1 year total shareholder return of 131.39%. However, the 5 year total shareholder return shows a decline of 21.26%, indicating that this momentum is more recent than long standing.

If you are looking beyond Exact Sciences, this could be a good moment to see what else is moving in healthcare related AI, using our screener as a starting point for fresh ideas with 36 healthcare AI stocks

With the shares near US$103.94, a value score of 5, an intrinsic discount figure of 31.25% and a small gap to analyst targets, you have to ask: is there still an entry point here, or is future growth already priced in?

Most Popular Narrative: 2% Undervalued

Exact Sciences' most followed narrative pegs fair value at about US$105.81, only slightly above the last close of US$103.94. This keeps attention firmly on the assumptions behind that estimate.

The analyst price target for Exact Sciences has been adjusted to reflect a revised view of slightly higher long term revenue growth and profit margins, along with a modestly higher discount rate and a lower assumed future P/E multiple, resulting in a new target of $105.81, unchanged from the prior target of $105.81.

Read the complete narrative.

Want to see what justifies that tight gap between price and fair value? The narrative leans on faster revenue, improving margins and a premium future earnings multiple, all filtered through a specific discount rate and timeframe.

Result: Fair Value of $105.81 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on execution, with Cologuard concentration and uncertainty around returns from high R&D and acquisition spending both capable of quickly challenging that underpriced story.

Find out about the key risks to this Exact Sciences narrative.

Next Steps

With sentiment this mixed, it makes sense to look past the headlines, review the underlying data yourself and decide how convincing the reward profile really is. To see what investors are optimistic about, take a closer look at the 4 key rewards

Looking for more investment ideas?

If Exact Sciences has your attention, do not stop here. Broaden your watchlist now or you risk missing other opportunities that fit your style.

• Target reliable income by checking out dividend payers that stand out as 15 dividend fortresses.
• Hunt for quality at a discount by reviewing 49 high quality undervalued stocks that combine fundamentals with attractive prices.
• Prioritise resilience by focusing on 76 resilient stocks with low risk scores that score well on stability and downside protection.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com